Search Results for: 19

— Mark Pimentel, MD, FRCP(C) to Review IBS-C Patient Data from Two SYN-010 Phase 2 Clinical Trials — — Conference Call Scheduled on Monday, May 23, 2016, at 8:30 a.m. (EDT) — ROCKVILLE, Md., May 17, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical stage company focused on developing therapeutics to protect the […]

— SYN-004 Degraded IV Ceftriaxone in the Presence of a Proton Pump Inhibitor in the Gastrointestinal Tract without Affecting Antibiotic Levels in the Bloodstream — — Two Poster Presentations Planned for ASM Microbe 2016, Including Detailed Data from Two SYN-004 Phase 2a Open-Label Clinical Trials — ROCKVILLE, Md., May16, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE

— Company Expands Strategic Partnering Efforts of Late-Stage GI Microbiome-Focused Clinical Programs — ROCKVILLE, Md., May 11, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical stage company focused on developing therapeutics to protect the gut microbiome, announced Isaac J. Bright, MD, has joined the Company in the new position of Vice President,

— Appointment Reflects Company’s Late-Stage Clinical Focus and Plans to Prepare for Commercialization — ROCKVILLE, Md., May 9, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical stage company focused on developing therapeutics to protect the gut microbiome, announced Deb Mathews, PharmD, has joined the Company in the new position of Vice President,

— Positioned to Initiate Phase 3 Clinical Trial for SYN-010 for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in 2H 2016 — — Two SYN-010 Posters Scheduled for Presentation at Digestive Disease Week (DDW 2016), Including Additional Positive Results from Two Phase 2 Clinical Trials — — Conference Call Today, May 5, 2016,

— Conference Call Scheduled for Thursday, May 5, 2016 at 4:30 p.m. EDT — ROCKVILLE, Md., April, 26, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical stage company focused on developing therapeutics to protect the gut microbiome, announced today that the Company intends to release its operational highlights and financial results for the

— Reported Positive Topline Data from Phase 2 Clinical Trials of SYN-010 for Irritable Bowel Syndrome with Constipation and SYN-004 for Prevention of C. difficile Infection and Antibiotic-Associated Diarrhea — — Expect to Initiate Phase 3 Clinical Trials in 2016 — — Conference Call Today, March 10, 2016, at 4:30 p.m. (EST) — ROCKVILLE, Md.,

ROCKVILLE, Md., March 9, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical stage company focused on developing therapeutics to protect the gut microbiome, announced today that Jeffrey Riley, President & Chief Executive Officer, is scheduled to present at the 28th Annual ROTH Conference being held March 14-16 at the Ritz-Carlton, Laguna Niguel in

— Conference Call Scheduled for Thursday, March 10, 2016 at 4:30 p.m. EST — ROCKVILLE, Md., March 3, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical stage company focused on developing therapeutics to protect the gut microbiome, intends to release its financial results for the year ended December 31, 2015 on Thursday, March

— New Allowances Bolster Strong SYN-004 Patent Estate — ROCKVILLE, Md., March 1, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical stage company focused on developing therapeutics to protect the gut microbiome, announced today that the U.S. Patent and Trademark Office (USPTO) issued Notices of Allowance for three patent applications which cover composition